Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Autologous cellular immunotherapy
5 evidence topics · 3 sources
FDA-approved indication and dosing
Asymptomatic or minimally symptomatic disease: trial population
Asymptomatic or minimally symptomatic disease: overall survival versus control
| Study | Sipuleucel-T, median months (95% CI) | Control, median months (95% CI) | Hazard ratio | Hazard ratio 95% CI |
|---|---|---|---|---|
| Study 1 | “25.8 (22.8, 27.7)” | “21.7 (17.7, 23.8)” | “0.775” | “(0.614, 0.979)” |